Atossa Therapeutics (NASDAQ:ATOS) Stock Price Passes Above 200-Day Moving Average - Time to Sell?

Atossa Therapeutics, Inc. (NASDAQ:ATOS - Get Free Report) shares passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.91 and traded as high as $0.96. Atossa Therapeutics shares last traded at $0.87, with a volume of 946,179 shares.

Analysts Set New Price Targets

ATOS has been the subject of several analyst reports. HC Wainwright restated a "buy" rating and issued a $7.00 target price on shares of Atossa Therapeutics in a research note on Wednesday, March 26th. Ascendiant Capital Markets lifted their target price on Atossa Therapeutics from $7.00 to $7.25 and gave the company a "buy" rating in a report on Monday, April 21st.

Atossa Therapeutics Trading Down 7.6%

The firm has a market cap of $112.47 million, a PE ratio of -3.96 and a beta of 1.01. The stock has a fifty day simple moving average of $0.74 and a two-hundred day simple moving average of $0.91.

Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01. As a group, sell-side analysts predict that Atossa Therapeutics, Inc. will post -0.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Gallagher Capital Advisors LLC purchased a new position in shares of Atossa Therapeutics during the fourth quarter worth about $25,000. Millennium Management LLC purchased a new position in shares of Atossa Therapeutics during the fourth quarter worth about $28,000. Two Sigma Advisers LP grew its holdings in shares of Atossa Therapeutics by 214.1% during the fourth quarter. Two Sigma Advisers LP now owns 42,400 shares of the company's stock worth $40,000 after purchasing an additional 28,900 shares in the last quarter. Intech Investment Management LLC grew its holdings in shares of Atossa Therapeutics by 224.0% during the fourth quarter. Intech Investment Management LLC now owns 62,844 shares of the company's stock worth $59,000 after purchasing an additional 43,449 shares in the last quarter. Finally, Wells Fargo & Company MN grew its holdings in shares of Atossa Therapeutics by 30.7% during the fourth quarter. Wells Fargo & Company MN now owns 71,720 shares of the company's stock worth $68,000 after purchasing an additional 16,853 shares in the last quarter. Hedge funds and other institutional investors own 12.74% of the company's stock.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.